Navigation Links
Anti-clotting agent helps reduce the incidence and impact of stent thrombosis during PCI
Date:3/27/2014

WASHINGTON, DC March 27, 2014 A new angiographic analysis of the CHAMPION PHOENIX trial examined the incidence and impact of stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI). Results of the study were released today and will be presented March 30 at the American College of Cardiology 63rd Annual Scientific Session.

CHAMPION PHOENIX was a prospective, double-blind, active-controlled trial which randomized 11,145 patients to receive intravenous cangrelor or oral clopidogrel administered at the time of PCI. In a previous analysis presented at TCT 2013 and published in the Journal of the American College of Cardiology, cangrelor significantly reduced periprocedural and 30-day ischemic events in patients undergoing PCI.

In this new analysis, an independent core laboratory (CRF) blinded to the treatment performed the angiographic analysis of 10,939 of the randomized patients. Stent thrombosis was defined as the occurrence of either intraprocedural ST (IPST) or ARC defined ST (definite or probable). Adverse events were adjudicated by an independent clinical events committee.

ST occurred in 120 patients (1.1 percent) at 48 hours and in 175 patients (1.6 percent) at 30 days. The occurrence of ST at 48 hours and 30 days was associated with a marked increase in 30-day mortality (OR [95%CI] = 15.3 [8.6, 27.2], p<0.001; and 55.2 [36.6, 83.3] p<0.001, respectively). IPST, ARC acute ST (≤24 hrs), and ARC subacute ST (1-30 days) occurred in 89 (0.8 percent), 32 (0.3 percent), and 60 (0.5 percent) patients respectively. Each type of ST was also associated with an increase in 30-day mortality (IPST: 17.4 [8.4, 36.1], p<0.001, ARC acute ST: 43.3 [18.1, 103.5], p<0.001, ARC sub-acute ST: 189.1, [107.9, 331.4], p<0.001).

"Regardless of the exact type of stent thrombosis, it remains associated with a high rate of death," stated Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart & Vascular Center, Professor of Medicine at Harvard Medical School, and Co-Chair of the CHAMPION program.

Cangrelor was associated with a significant reduction in 48-hour (0.8 vs. 1.4 percent, p=0.01) and 30-day ST (1.3 vs. 1.9 percent, p=0.01), compared with clopidogrel. Cangrelor also had consistent effect in IPST (0.6 vs. 1.0 percent, p=0.04), acute ARC ST (0.2 vs. 0.4 percent, p=0.8), and sub-acute ARC ST (0.5 vs. 0.6 percent, p=0.60). After multivariable analysis, the use of cangrelor was identified as an independent predictor of freedom of ST at 30 days.

"The benefits of cangrelor were consistent across all these different categories of stent thrombosis," stated Robert A. Harrington, MD, Chairman of Medicine and Bloomfield Professor of Medicine at Stanford University, and Co-Chair of the CHAMPION program.

"In the large-scale CHAMPION PHOENIX trial, the occurrence of stent thrombosis was strongly associated with increased mortality. Cangrelor use resulted in a significant reduction in ST, with consistent outcomes on intraprocedural, and outside the cath lab acute and sub-acute ARC defined ST," stated lead investigator Philippe Gnreux, MD. Dr. Gnreux is Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center. The CRF Angiographic Core Lab conducted the analyses.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Anti-clotting drugs yield similar results
2. Anti-clotting therapy may be used too often following orthopaedic surgery or trauma
3. Discovery could lead to anti-clotting drugs with less risk of bleeding
4. Pradaxa Bleeding Allegations Lawyer: Resource4thePeople Reports New Study May Produce Treatment to Reverse Anti-Clotting Medication Effects
5. Pig stomach mucins are effective as anti-viral agents for consumer products
6. Imaging agents predict breast cancer response to endocrine therapy
7. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
8. New substances 15,000 times more effective in destroying chemical warfare agents
9. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
10. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
11. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... The American Hospital Association (AHA) has ... Highmark Health company, to its Board of Trustees for a three-year term beginning January ... care provider organizations and individuals that are committed to the improvement of health in ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... ComplyPAK™ Compliance Management System has assisted multiple clients in successfully passing audits ... Service Organization Control Level 2 (AICPA SOC Level 2), and State Data Use ...
(Date:8/19/2017)... California (PRWEB) , ... August 18, 2017 , ... ... a partnership aimed at creating a transparent, verifiable database to help the cannabis ... distributed ledger technology, Paragon hopes to deliver a faster technology with lower fees. ...
(Date:8/19/2017)... ... , ... Yesterday, the President of the United States retracted his condemnation of ... not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... against all forms of such hatred and discrimination in this country and globally. ...
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made their ... to an ambitious venture that conjoined the passions of an NBA star, a Liberty ... Liberty community. These shoes will save lives from the rampant infections transmitted through the ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... Aug. 17, 2017 Bio-Ess Laboratories, LLC Chief Science Officer, Dr. ... and present new data on Cell-Ess® Universal Titer Boost at ... Boston, MA August 21-25.  The Bioprocessing Summit convenes more than ... ... ...
(Date:8/15/2017)... announced today that its fully owned USA -operating ... City Office in Yonkers, New York to ... 2 ) homecare therapy. This new East Coast location has also ... the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New York ...
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
Breaking Medicine Technology: